Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Dopamine agonist-resistant prolactinomas.

Oh MC, Aghi MK.

J Neurosurg. 2011 May;114(5):1369-79. doi: 10.3171/2010.11.JNS101369. Review.

PMID:
21214334
2.

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM.

Pituitary. 2007;10(1):81-6.

PMID:
17285366
3.
4.

Women with prolactinomas presented at the postmenopausal period.

Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A.

Endocrine. 2014 Dec;47(3):889-94. doi: 10.1007/s12020-014-0259-1.

PMID:
24711223
5.

Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.

Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J.

Acta Neurochir (Wien). 2005 Jul;147(7):751-7; discussion 757-8.

PMID:
15971099
6.

Update on prolactinomas. Part 2: Treatment and management strategies.

Wong A, Eloy JA, Couldwell WT, Liu JK.

J Clin Neurosci. 2015 Oct;22(10):1568-74. doi: 10.1016/j.jocn.2015.03.059. Review.

PMID:
26243714
7.

Resistant prolactinomas.

Vasilev V, Daly AF, Vroonen L, Zacharieva S, Beckers A.

J Endocrinol Invest. 2011 Apr;34(4):312-6. doi: 10.3275/7604. Review.

PMID:
21406957
8.

Falsely low serum prolactin in two cases of invasive macroprolactinoma.

Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G.

Pituitary. 2002;5(4):261-5.

PMID:
14558675
9.

Temozolomide in the management of dopamine agonist-resistant prolactinomas.

Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJ.

Clin Endocrinol (Oxf). 2012 Jun;76(6):877-86. doi: 10.1111/j.1365-2265.2012.04373.x. Review.

PMID:
22372583
10.

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.

Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M.

Clin Endocrinol (Oxf). 1996 Jun;44(6):711-6.

PMID:
8759184
11.

PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.

Cristina C, Díaz-Torga GS, Goya RG, Kakar SS, Perez-Millán MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D.

Mol Cancer. 2007 Jan 12;6:4.

12.

Giant prolactinomas: clinical management and long-term follow up.

Shrivastava RK, Arginteanu MS, King WA, Post KD.

J Neurosurg. 2002 Aug;97(2):299-306.

PMID:
12186457
13.

The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Recouvreux MV, Camilletti MA, Rifkin DB, Díaz-Torga G.

J Endocrinol. 2016 Mar;228(3):R73-83. doi: 10.1530/JOE-15-0451. Review.

14.

Management of resistant prolactinomas.

Olafsdottir A, Schlechte J.

Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):552-61. Review.

PMID:
17024154
15.

Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.

Primeau V, Raftopoulos C, Maiter D.

Eur J Endocrinol. 2012 May;166(5):779-86. doi: 10.1530/EJE-11-1000.

16.

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.

Gao H, Wang F, Lan X, Li C, Feng J, Bai J, Cao L, Gui S, Hong L, Zhang Y.

BMC Cancer. 2015 Apr 12;15:272. doi: 10.1186/s12885-015-1267-0.

17.

Giant prolactinomas presenting as skull base tumors.

Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R, Cantore G.

Surg Neurol. 2002 Feb;57(2):99-103; discussion 103-4.

PMID:
11904200
18.

[Dopamine-agonist resistant prolactinomas: diagnosis and management].

Musolino NR, Passos VQ.

Arq Bras Endocrinol Metabol. 2005 Oct;49(5):641-50. Review. Portuguese.

19.

Diagnosis and drug therapy of prolactinoma.

Ciccarelli E, Camanni F.

Drugs. 1996 Jun;51(6):954-65. Review.

PMID:
8736617
20.

Giant prolactinomas: the therapeutic approach.

Moraes AB, Silva CM, Vieira Neto L, Gadelha MR.

Clin Endocrinol (Oxf). 2013 Oct;79(4):447-56. doi: 10.1111/cen.12242. Review.

PMID:
23662975

Supplemental Content

Support Center